Pharmacokinetics of alizapride in children receiving chemotherapy for solid tumour.
The purpose of the present study was to determine the pharmacokinetics of alizapride to optimize its use in children aged 1 month to 15 years old who were receiving chemotherapy. Seventeen children were given a single 4 mg/kg alizapride infusion prior to the administration of cytostatic drugs. Blood and urine samples were collected within 10 h after onset of the infusion. Kinetic parameters were calculated and showed a decrease in plasma clearance expressed per unit of body weight with age. The current data suggest that dosage expressed per unit of body weight should be higher in children than in adults and higher in infants than in children.
Rey
E
E
Pharmacologie Périnatale et Pédiatrique, Hôpital Saint-Vincent de Paul, Université René Descartes Paris V, France. elisabeth.rey@svp.ap-hop-paris.fr
Stettler
E
E
D'athis
P
P
Pons
G
G
D000293:Adolescent; D000932:Antiemetics / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019540:Area Under Curve; D002648:Child; D002675:Child, Preschool; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007700:Kinetics; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011759:Pyrrolidines / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D000932:Antiemetics; D000970:Antineoplastic Agents; D011759:Pyrrolidines; C033968:alizapride